{
    "clinical_study": {
        "@rank": "119609", 
        "brief_summary": {
            "textblock": "This is a randomized, open-label, crossover study to examine the bioavailability of\n      pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes\n      mellitus using insulin."
        }, 
        "brief_title": "Evaluation of the Bioavailability of Pramlintide", 
        "completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HbA1c value between 6-12%\n\n          -  BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2\n\n          -  Consistent insulin regimen for 2 months prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "July 30, 2002", 
        "id_info": {
            "nct_id": "NCT00042471", 
            "org_study_id": "137-153"
        }, 
        "intervention": {
            "intervention_name": "Pramlintide acetate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pramlintide", 
                "Islet Amyloid Polypeptide"
            ]
        }, 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }, 
                    "name": "New Orleans Center for Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "DaVita Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "CEDRA Clinical Research, LLC"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042471"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }, 
    "geocoordinates": {
        "CEDRA Clinical Research, LLC": "30.267 -97.743", 
        "DaVita Clinical Research": "44.98 -93.264", 
        "New Orleans Center for Clinical Research": "29.951 -90.072", 
        "Orlando Clinical Research Center": "28.538 -81.379"
    }
}